Evidence map›Paper›PMID 42297731›Full record

ArticleImmunology2026

MOG-Peptide Synergizes With Rapamycin to Drive CD4

Mohammad Adeel Zafar, Taruna Lamba, Azeez Tehseen, Roman Sarkar, Sidhanta Nanda, Shivank Prajapati, Mohd Affan Khan, Jonaid Ahmad Malik, Mehdi Benamar, Louis-Marie Charbonnier and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mohammad Adeel ZafarImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Taruna LambaImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Azeez TehseenDepartment of Biological Sciences, Indian Institute of Science Education and Research, Mohali, India.
Roman SarkarDepartment of Biological Sciences, Indian Institute of Science Education and Research, Mohali, India.
Sidhanta NandaImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Shivank PrajapatiImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Mohd Affan KhanImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Jonaid Ahmad MalikImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.ORCID https://orcid.org/0000-0001-6684-6744
Mehdi BenamarDivision of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-1532-8642
Louis-Marie CharbonnierDivision of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.
Sharvan SehrawatDepartment of Biological Sciences, Indian Institute of Science Education and Research, Mohali, India.
Javed Naim AgrewalaImmunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.

Funding

Department of Science and Technology, Ministry of Science and Technology, India EMR/2017/002059Department of Science and Technology, Ministry of Science and Technology, India JCB/2017/000048Indian Council of Medical Research 5/8/5/17/ITRC/Vaccine Trail/2022/ECD-1Scheme for Promotion of Academic and Research Collaboration P1138SPARC-Minister of Education and Indian Council of Medical Research, India 9-306/2018/IITRPR//582
6 · The paper itself

Abstract

During multiple sclerosis, immune responses directed against myelin oligodendrocyte glycoprotein (MOG) contribute to demyelination and neuroinflammation. Among these, Th17 cells play an important role in promoting inflammatory damage to the myelin sheath and disrupting the integrity of blood brain barrier fibres. Despite advances in immunotherapy, there is no vaccine or durable cure for the disease. Regulatory T cells (Tregs) play a protective role against Th17-mediated damage of myelin sheath. In this study, we investigated whether rapamycin, a well-characterized mTOR inhibitor known to favour differentiation and metabolic reprogramming of Tregs, could synergize with MOG

Indexed as

CD4-Positive T-LymphocytesEncephalomyelitis, Autoimmune, ExperimentalMyelin-Oligodendrocyte GlycoproteinPeptide FragmentsSirolimusT-Lymphocytes, RegulatoryAnimalsCell DifferentiationFemaleMiceMice, Inbred C57BLTh17 CellsMyelin-Oligodendrocyte Glycoproteinmyelin oligodendrocyte glycoprotein (35-55)Peptide FragmentsSirolimusautoimmune diseasesEAEMOGrapamycinTregs

Identifiers

PMID42297731
PMCPMC13432069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.